赛诺菲拟出资3.08亿欧元收购细胞疗法公司Kiadis
© Reuters. 赛诺菲(SNY.US)拟出资3.08亿欧元收购细胞疗法公司Kiadis
智通财经APP获悉，赛诺菲 (NASDAQ:SNY)宣布，公司已与细胞疗法公司Kiadis签署了股权收购协议。根据协议，赛诺菲将公开出价，以每股5.45欧元的价格收购后者全部股本，总计调整后的股本价值为3.08亿欧元。
报道称，今年7月份，Kiadis已与赛诺菲达成研发许可协议，将其此前未公开的K-NK004项目的独家研发许可授予赛诺菲。K-NK004是一款使用基因工程敲除CD38表达的NK细胞疗法。赛诺菲计划将它与该公司开发的CD38抗体Sarclisa联用，用于治疗多发性骨髓瘤患者。
Disclaimer: The content above represents only the views of the author or guest. It does not represent any views or positions of FOLLOWME and does not mean that FOLLOWME agrees with its statement or description, nor does it constitute any investment advice. For all actions taken by visitors based on information provided by the FOLLOWME community, the community does not assume any form of liability unless otherwise expressly promised in writing.
FOLLOWME Trading Community Website: https://www.followme.com
Hot
No comment on record. Start new comment.